Trial Outcomes & Findings for Study to Assess AFM24 in Advanced Solid Cancers (NCT NCT04259450)

Last Updated: 2025-07-17

Results Overview

The number of patients with dose limiting toxicities (DLTs) in the first cycle, as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0. DLT is defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to underlying disease, disease progression, inter-current illness, or concomitant medications, that occurs ≤28 days following the first dose of AFM24 (Cycle 1).

Recruitment status

TERMINATED

Study phase

PHASE1/PHASE2

Target enrollment

85 participants

Primary outcome timeframe

During Cycle 1 (up to 28 days)

Results posted on

2025-07-17

Participant Flow

This study was a phase 1/2a open-label, multicenter study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of AFM24 in patients with advanced solid cancers

Phase 1 subjects enrolled if they had a tumor known to express Epidermal Growth Factor Receptor (EGFR), Phase 2 subjects were screened for positive EGFR from tumor site. Specialists assessed the subjects, and they were enrolled in the study if they met all inclusion criteria and none of the exclusion criteria.

Participant milestones

Participant milestones
Measure	Phase 1- 14 mg Cohort 1 Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).	Phase 2- CRC 480 mg Cohort A Subjects with microsatellite stable (MSS) colorectal cancer (CRC) with rat sarcoma gene (RAS) wild-type tumor expressing EGFR who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).	Phase 2- ccRCC 480 mg Cohort B Subjects with clear cell renal cell carcinoma (ccRCC) expressing EGFR who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).	Phase 2- NSCLC 480 mg Cohort C Subjects with advanced or metastatic (non-small cell lung cancer) NSCLC with an epidermal growth factor receptor (EGFR) mutation who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Overall Study STARTED	2	6	4	5	6	6	6	19	8	23
Overall Study COMPLETED	0	0	0	0	0	0	0	0	0	0
Overall Study NOT COMPLETED	2	6	4	5	6	6	6	19	8	23

Reasons for withdrawal

Reasons for withdrawal
Measure	Phase 1- 14 mg Cohort 1 Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).	Phase 2- CRC 480 mg Cohort A Subjects with microsatellite stable (MSS) colorectal cancer (CRC) with rat sarcoma gene (RAS) wild-type tumor expressing EGFR who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).	Phase 2- ccRCC 480 mg Cohort B Subjects with clear cell renal cell carcinoma (ccRCC) expressing EGFR who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).	Phase 2- NSCLC 480 mg Cohort C Subjects with advanced or metastatic (non-small cell lung cancer) NSCLC with an epidermal growth factor receptor (EGFR) mutation who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Overall Study Adverse event/ Toxicity	0	3	0	1	0	0	0	1	0	3
Overall Study Disease progression	2	3	4	4	6	6	6	15	6	18
Overall Study Death	0	0	0	0	0	0	0	1	1	0
Overall Study Withdrawal by Subject	0	0	0	0	0	0	0	1	0	0
Overall Study Other than listed	0	0	0	0	0	0	0	1	1	2

Baseline Characteristics

Study to Assess AFM24 in Advanced Solid Cancers

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Phase 1- 14 mg Cohort 1 n=2 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=6 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=4 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 n=5 Participants Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 n=6 Participants Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 n=6 Participants Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 n=6 Participants Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).	Phase 2- CRC 480 mg Cohort A n=19 Participants Subjects with microsatellite stable (MSS) colorectal cancer (CRC) with rat sarcoma gene (RAS) wild-type tumor expressing EGFR who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).	Phase 2- ccRCC 480 mg Cohort B n=8 Participants Subjects with clear cell renal cell carcinoma (ccRCC) expressing EGFR who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).	Phase 2- NSCLC 480 mg Cohort C n=23 Participants Subjects with advanced or metastatic (non-small cell lung cancer) NSCLC with an epidermal growth factor receptor (EGFR) mutation who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).	Total n=85 Participants Total of all reporting groups
Age, Continuous	73.0 Years STANDARD_DEVIATION 0.00 • n=5 Participants	54.7 Years STANDARD_DEVIATION 14.12 • n=7 Participants	47.3 Years STANDARD_DEVIATION 20.89 • n=5 Participants	58.4 Years STANDARD_DEVIATION 11.35 • n=4 Participants	57.7 Years STANDARD_DEVIATION 16.99 • n=21 Participants	59.7 Years STANDARD_DEVIATION 12.08 • n=8 Participants	53.8 Years STANDARD_DEVIATION 10.57 • n=8 Participants	62.7 Years STANDARD_DEVIATION 9.32 • n=24 Participants	67.1 Years STANDARD_DEVIATION 15.00 • n=42 Participants	61.1 Years STANDARD_DEVIATION 11.83 • n=42 Participants	60.2 Years STANDARD_DEVIATION 12.80 • n=42 Participants
Sex: Female, Male Female	1 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	4 Participants n=4 Participants	3 Participants n=21 Participants	2 Participants n=8 Participants	1 Participants n=8 Participants	5 Participants n=24 Participants	2 Participants n=42 Participants	10 Participants n=42 Participants	29 Participants n=42 Participants
Sex: Female, Male Male	1 Participants n=5 Participants	5 Participants n=7 Participants	4 Participants n=5 Participants	1 Participants n=4 Participants	3 Participants n=21 Participants	4 Participants n=8 Participants	5 Participants n=8 Participants	14 Participants n=24 Participants	6 Participants n=42 Participants	13 Participants n=42 Participants	56 Participants n=42 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	2 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	1 Participants n=24 Participants	1 Participants n=42 Participants	1 Participants n=42 Participants	9 Participants n=42 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	2 Participants n=5 Participants	2 Participants n=7 Participants	3 Participants n=5 Participants	3 Participants n=4 Participants	5 Participants n=21 Participants	6 Participants n=8 Participants	6 Participants n=8 Participants	18 Participants n=24 Participants	7 Participants n=42 Participants	21 Participants n=42 Participants	73 Participants n=42 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	3 Participants n=42 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	1 Participants n=8 Participants	10 Participants n=24 Participants	1 Participants n=42 Participants	18 Participants n=42 Participants	32 Participants n=42 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Black or African American	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	2 Participants n=42 Participants
Race (NIH/OMB) White	1 Participants n=5 Participants	4 Participants n=7 Participants	4 Participants n=5 Participants	4 Participants n=4 Participants	4 Participants n=21 Participants	5 Participants n=8 Participants	5 Participants n=8 Participants	9 Participants n=24 Participants	7 Participants n=42 Participants	5 Participants n=42 Participants	48 Participants n=42 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	3 Participants n=42 Participants

PRIMARY outcome

Timeframe: During Cycle 1 (up to 28 days)

Population: The Dose-Determining Set (DDS): All patients in the safety set (all patients who received at least one dose of AFM24), who had either (a) experienced DLT at any time during Cycle 1, or (b) met the minimum safety evaluation requirements without experiencing DLT within Cycle 1.

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=2 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=4 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=4 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 n=4 Participants Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 n=5 Participants Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 n=6 Participants Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 n=6 Participants Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 1: The Number of Subjects With Dose Limiting Toxicities (DLTs) During Cycle 1	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Up to approximately 16 weeks.

Population: The safety set: All patients who received at least one dose of AFM24.

Overall response as defined by achieving confirmed CR and/or PR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Partial or complete response needs to be confirmed with repeated assessment at least 4 weeks after the initial assessment.

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=19 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=8 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=23 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 2a: Overall Response Rate (Complete Response [CR] + Partial Response [PR])	0 Participants	0 Participants	2 Participants	—	—	—	—

SECONDARY outcome

Timeframe: From the start of first infusion till the last infusion + 30 days, up to approximately 43 weeks.

Population: The safety set: All patients who received at least one dose of AFM24.

Adverse Events (AEs) will be summarized with patient counts by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Classes (SOCs) and Preferred Terms (PTs).

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=2 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=6 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=4 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 n=5 Participants Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 n=6 Participants Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 n=6 Participants Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 n=6 Participants Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 1: The Number of Subjects With Treatment-emergent Adverse Events (TEAEs)	2 Participants	6 Participants	4 Participants	5 Participants	6 Participants	6 Participants	6 Participants

SECONDARY outcome

Timeframe: From the start of first infusion till the last infusion + 30 days, up to approximately 43 weeks.

Population: The safety set: All patients who received at least one dose of AFM24.

Serious adverse Events (SAEs) will be summarized with patient counts by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Classes (SOCs) and Preferred Terms (PTs).

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=2 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=6 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=4 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 n=5 Participants Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 n=6 Participants Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 n=6 Participants Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 n=6 Participants Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 1: The Number of Subjects With Serious Adverse Events (SAEs)	2 Participants	3 Participants	2 Participants	2 Participants	4 Participants	3 Participants	2 Participants

SECONDARY outcome

Timeframe: Pre-dose (2 hours maximum) and 15, 30, 45 min after start of infusion (SOI) and end of infusion (EOI) and 1, 4, 18, 24, 48, 144 hours after EOI on Cycle 1 Day 22.

Population: The Pharmacokinetic set: all subjects who received at least one adequately documented dose of study drug and had at least one adequately documented post dose pharmacokinetic (PK) measurement. Subjects were excluded if they did not have at least two quantifiable concentration values, two of which must have occurred after Tmax, this was the case for one subject in Cohort 6.

Area under the concentration-time curve from time 0 to time tau (7 days) of AFM24 in plasma (AUC0-168)

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=2 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=3 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=4 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 n=4 Participants Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 n=6 Participants Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 n=5 Participants Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 n=6 Participants Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 1: Area Under the Concentration-time Curve From Time 0 to Time Tau (7 Days) of AFM24 in Plasma	53400 hours*nanogram /milliLiter Standard Deviation 61700	549000 hours*nanogram /milliLiter Standard Deviation 254000	1290000 hours*nanogram /milliLiter Standard Deviation 395000	4940000 hours*nanogram /milliLiter Standard Deviation 1370000	18100000 hours*nanogram /milliLiter Standard Deviation 6120000	28700000 hours*nanogram /milliLiter Standard Deviation 7620000	40200000 hours*nanogram /milliLiter Standard Deviation 12000000

SECONDARY outcome

Timeframe: Pre-dose (2 hours maximum) and 15, 30, 45 min after start of infusion (SOI) and end of infusion (EOI) and 1, 4, 18, 24, 48, 144 hours after EOI on Cycle 1 Day 1 and on pre-dose (2 hours maximum) Cycle 1 Day 8.

Population: The Pharmacokinetic set: all subjects who received at least one adequately documented dose of study drug and had at least one adequately documented post dose PK measurement.

Maximum measured concentration (Cmax) of AFM24 in plasma

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=2 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=3 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=4 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 n=4 Participants Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 n=6 Participants Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 n=6 Participants Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 n=6 Participants Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 1: Maximum Plasma Concentration (Cmax) of AFM24	3290 nanogram /milliLiter Standard Deviation 2860	13200 nanogram /milliLiter Standard Deviation 3100	29200 nanogram /milliLiter Standard Deviation 6620	60900 nanogram /milliLiter Standard Deviation 17600	204000 nanogram /milliLiter Standard Deviation 55600	298000 nanogram /milliLiter Standard Deviation 71100	354000 nanogram /milliLiter Standard Deviation 104000

SECONDARY outcome

Timeframe: Pre-dose (2 hours maximum) and 15, 30, 45 min after start of infusion (SOI) and end of infusion (EOI) and 1, 4, 18, 24, 48, 144 hours after EOI on Cycle 1 Day 22.

Population: The Pharmacokinetic set: all subjects who received at least one adequately documented dose of study drug and had at least one adequately documented post dose PK measurement.

First time to maximum observed concentration of AFM24 sampled during a dosing interval.

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=2 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=3 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=4 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 n=4 Participants Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 n=6 Participants Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 n=6 Participants Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 n=6 Participants Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 1: Time of Maximum Observed Concentration (Tmax) of AFM24	1.84 hours Standard Deviation 1.19	3.43 hours Standard Deviation 1.97	5.63 hours Standard Deviation 1.71	5.64 hours Standard Deviation 1.30	7.18 hours Standard Deviation 0.564	7.52 hours Standard Deviation 1.38	5.21 hours Standard Deviation 0.280

SECONDARY outcome

Population: The Pharmacokinetic set: all subjects who received at least one adequately documented dose of study drug and had at least one adequately documented post dose PK measurement.

Minimum measured concentration (Cmin) of AFM24 in plasma

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=2 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=3 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=4 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 n=4 Participants Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 n=6 Participants Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 n=6 Participants Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 n=6 Participants Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 1: Minimum Plasma Concentration (Cmin) of AFM24	32.7 ng/mL Standard Deviation 46.2	311 ng/mL Standard Deviation 281	810 ng/mL Standard Deviation 482	12000 ng/mL Standard Deviation 3540	73800 ng/mL Standard Deviation 40600	117000 ng/mL Standard Deviation 49600	233000 ng/mL Standard Deviation 113000

SECONDARY outcome

Timeframe: Pre-dose cycle 1 Day 1 and end of treatment, up to approximately 39 weeks.

Population: The safety set: All patients who received at least one dose of AFM24.

The number of subjects who developed anti-drug antibodies (ADAs) at any time during the study.

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=2 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=6 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=4 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 n=5 Participants Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 n=6 Participants Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 n=6 Participants Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 n=6 Participants Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 1: The Number of Subjects Who Developed Anti-drug Antibodies (ADAs) and Neutralizing ADAs During Treatment With AFM24	1 Participants	4 Participants	2 Participants	3 Participants	1 Participants	0 Participants	1 Participants

SECONDARY outcome

Timeframe: From the start of first infusion till the last infusion + 30 days, up to approximately 43 weeks.

Population: The safety set: All patients who received at least one dose of AFM24.

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=2 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=6 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=4 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 n=5 Participants Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 n=6 Participants Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 n=6 Participants Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 n=6 Participants Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 1: Overall Response Rate (Complete Response (CR) + Partial Response (PR))	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: through study completion (estimated up to 24 weeks)

Population: No subjects had a response.

The DOR defined as time from first assessment of partial response (PR) or complete response (CR) to follow-on first assessment of progressive disease will be summarized by descriptive statistics including median DOR and where appropriate the respective 95% confidence intervals (CIs).

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From the start of first infusion till the last infusion + 30 days, up to approximately 43 weeks.

Population: The safety set: All patients who received at least one dose of AFM24.

Disease control as defined by achieving CR and/or PR and/or SD assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=2 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=6 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=4 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 n=5 Participants Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 n=6 Participants Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 n=6 Participants Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 n=6 Participants Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 1: Disease Control Rate (Complete Response (CR) + Partial Response (PR) +Stable Disease (SD))	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	2 Participants	1 Participants

SECONDARY outcome

Timeframe: From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks.

Population: The safety set: All patients who received at least one dose of AFM24.

Adverse Events (AEs) will be summarized with patient counts by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Classes (SOCs) and Preferred Terms (PTs).

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=19 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=8 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=23 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 2a: The Number of Subjects With Treatment-emergent Adverse Events (TEAEs)	19 Participants	8 Participants	23 Participants	—	—	—	—

SECONDARY outcome

Timeframe: From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks.

Population: The safety set: All patients who received at least one dose of AFM24.

Serious adverse Events (SAEs) will be summarized with patient counts by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Classes (SOCs) and Preferred Terms (PTs).

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=19 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=8 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=23 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 2a: The Number of Subjects With Serious Adverse Events (SAEs)	8 Participants	6 Participants	8 Participants	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose (2 hours maximum) on Cycle 1 Day 22.

Population: The safety set: All patients who received at least one dose of AFM24.

Trough concentration (Ctrough) of AFM24 in plasma.

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=19 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=8 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=23 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 2a: Trough Concentration (Ctrough) of AFM24	69155.7 ng/mL (nanogram/milliliter) Standard Deviation 32573.34	77642.7 ng/mL (nanogram/milliliter) Standard Deviation 79113.19	84616.7 ng/mL (nanogram/milliliter) Standard Deviation 36176.09	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose (2 hours maximum) on Cycle 1 Day 22 and at end of infusion (EOI) on Cycle 1 Day 22.

Population: The safety set: All patients who received at least one dose of AFM24.

Maximum measured concentration (Cmax) of AFM24 in plasma.

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=19 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=8 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=23 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 2a: Maximum Plasma Concentration (Cmax) of AFM24	254285.7 ng/mL (nanogram/milliliter) Standard Deviation 145002.08	170428.6 ng/mL (nanogram/milliliter) Standard Deviation 71327.55	272111.1 ng/mL (nanogram/milliliter) Standard Deviation 111029.35	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose cycle 1 Day 1 and end of treatment, up to approximately 101 weeks.

Population: The safety set: All patients who received at least one dose of AFM24.

The number of subjects who developed anti-drug antibodies (ADAs) at any time during the study.

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=19 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=8 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=23 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 2a: The Number of Subjects Who Developed Anti-drug Antibodies (ADAs) During Treatment With AFM24	3 Participants	1 Participants	8 Participants	—	—	—	—

SECONDARY outcome

Timeframe: From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks.

Population: The safety set: All patients who received at least one dose of AFM24.

Overall response as defined by achieving confirmed CR and/or PR assessed by Central Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Partial or complete response needs to be confirmed with repeated assessment at least 4 weeks after the initial assessment.

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=19 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=8 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=23 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 2a: Overall Response Rate (Complete Response [CR] + Partial Response [PR]) Assessed by Central RECIST v1.1	0 Participants	0 Participants	0 Participants	—	—	—	—

SECONDARY outcome

Timeframe: From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks.

Population: All patients who received at least one dose of AFM24 and who had a response by RECIST v1.1 by Local Review.

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=2 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 2a: Duration of Response Rate (DOR) by RECIST v1.1 by Local Review	NA Months Interval 3.61 to Not enough events to calculate the data.	—	—	—	—	—	—

SECONDARY outcome

Timeframe: From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks.

Population: All patients who received at least one dose of AFM24 and who had a response by RECIST v1.1 by Central Review.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks.

Population: The safety set: All patients who received at least one dose of AFM24.

Disease control as defined by achieving CR and/or PR and/or SD assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Disease control was assessed by local RECIST v1.1 and by central RECIST v1.1.

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=19 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=8 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=23 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 2a: Disease Control Rate (Complete Response (CR) + Partial Response (PR) +Stable Disease (SD)) Local RECIST v1.1	2 Participants	2 Participants	9 Participants	—	—	—	—
Phase 2a: Disease Control Rate (Complete Response (CR) + Partial Response (PR) +Stable Disease (SD)) Central RECIST v1.1	1 Participants	0 Participants	2 Participants	—	—	—	—

SECONDARY outcome

Timeframe: From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks.

Population: The safety set: All patients who received at least one dose of AFM24.

Progression-Free Survival (PFS) was defined as (date of first progression - date of first study drug injection)/30.4375. PFS was measured by local and central assessments.

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=19 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=8 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=23 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 2a: Progression-free-survival (PFS) Local RECIST v1.1	1.61 Months Interval 1.15 to 1.64	2.55 Months Interval 0.43 to Not enough events to calculate the data.	3.68 Months Interval 1.61 to 5.36	—	—	—	—
Phase 2a: Progression-free-survival (PFS) Central RECIST v1.1	3.88 Months Interval 1.61 to 5.88	8.15 Months Interval 0.43 to Not enough events to calculate the data.	3.52 Months Interval 1.54 to 10.68	—	—	—	—

SECONDARY outcome

Timeframe: From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks.

Population: The safety set: All patients who received at least one dose of AFM24.

Overall Survival (OS) was defined as (date of death - date of first dose)/30.4375. Patients alive at the end of study will be censored on the last date of observation.

Outcome measures

Outcome measures
Measure	Phase 1- 14 mg Cohort 1 n=19 Participants Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=8 Participants Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=23 Participants Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Phase 2a: Overall Survival	6.64 Months Interval 3.88 to 10.71	8.87 Months Interval 0.43 to Not enough events to calculate the data.	NA Months Interval 9.26 to Not enough events to calculate the data.	—	—	—	—

Adverse Events

Phase 1- 14 mg Cohort 1

Serious events: 2 serious events

Other events: 2 other events

Deaths: 1 deaths

Phase 1- 40 mg Cohort 2

Serious events: 3 serious events

Other events: 5 other events

Deaths: 6 deaths

Phase 1- 80 mg Cohort 3

Serious events: 2 serious events

Other events: 4 other events

Deaths: 4 deaths

Phase 1- 160 mg Cohort 4

Serious events: 2 serious events

Other events: 5 other events

Deaths: 3 deaths

Phase 1- 320 mg Cohort 5

Serious events: 4 serious events

Other events: 6 other events

Deaths: 4 deaths

Phase 1- 480 mg Cohort 6

Serious events: 3 serious events

Other events: 6 other events

Deaths: 4 deaths

Phase 1- 720 mg Cohort 7

Serious events: 2 serious events

Other events: 6 other events

Deaths: 6 deaths

Phase 2- CRC 480 mg Cohort A

Serious events: 8 serious events

Other events: 19 other events

Deaths: 14 deaths

Phase 2- ccRCC 480 mg Cohort B

Serious events: 6 serious events

Other events: 8 other events

Deaths: 6 deaths

Phase 2- NSCLC 480 mg Cohort C

Serious events: 8 serious events

Other events: 22 other events

Deaths: 7 deaths

Serious adverse events

Serious adverse events
Measure	Phase 1- 14 mg Cohort 1 n=2 participants at risk Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=6 participants at risk Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=4 participants at risk Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 n=5 participants at risk Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 n=6 participants at risk Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 n=6 participants at risk Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 n=6 participants at risk Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).	Phase 2- CRC 480 mg Cohort A n=19 participants at risk Subjects with microsatellite stable (MSS) colorectal cancer (CRC) with rat sarcoma gene (RAS) wild-type tumor expressing EGFR who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).	Phase 2- ccRCC 480 mg Cohort B n=8 participants at risk Subjects with clear cell renal cell carcinoma (ccRCC) expressing EGFR who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).	Phase 2- NSCLC 480 mg Cohort C n=23 participants at risk Subjects with advanced or metastatic (non-small cell lung cancer) NSCLC with an epidermal growth factor receptor (EGFR) mutation who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Renal and urinary disorders Urinary tract obstruction	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Cardiac disorders Myocardial infarction	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Nervous system disorders Cerebral haemorrhage	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Nervous system disorders Epilepsy	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Nervous system disorders Seizure	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Cardiac disorders Sinus tachycardia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Abdominal pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	10.5% 2/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
General disorders Fatigue	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
General disorders Non-cardiac chest pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
General disorders Pain	50.0% 1/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Hepatobiliary disorders Cholangitis	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations COVID-19	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Cholangitis infective	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Pneumonia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Injury, poisoning and procedural complications Hip fracture	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	8.7% 2/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Metabolism and nutrition disorders Failure to thrive	50.0% 1/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastatic neoplasm	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Renal and urinary disorders Haematuria	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Tachypnoea	50.0% 1/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Blood and lymphatic system disorders Anaemia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Eye disorders Blindness	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
General disorders Asthenia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Hepatobiliary disorders Bile duct stenosis	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Hepatobiliary disorders Dilatation intrahepatic duct acquired	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Hepatobiliary disorders Jaundice cholestatic	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations COVID-19 pneumonia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Influenza	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Oesophageal candidiasis	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Sepsis	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Urinary tract infection	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Vascular device infection	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Anorectal infection	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Bacterial abscess central nervous system	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cancer pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Pulmonary haemorrhage	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Cardiac disorders Sinus bradycardia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.

Other adverse events

Other adverse events
Measure	Phase 1- 14 mg Cohort 1 n=2 participants at risk Subjects, with tumors known to express EGFR, who received 14 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 40 mg Cohort 2 n=6 participants at risk Subjects, with tumors known to express EGFR, who received 40 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 80 mg Cohort 3 n=4 participants at risk Subjects, with tumors known to express EGFR, who received 80 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 160 mg Cohort 4 n=5 participants at risk Subjects, with tumors known to express EGFR, who received 160 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 320 mg Cohort 5 n=6 participants at risk Subjects, with tumors known to express EGFR, who received 320 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 480 mg Cohort 6 n=6 participants at risk Subjects, with tumors known to express EGFR, who received 480 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.	Phase 1- 720 mg Cohort 7 n=6 participants at risk Subjects, with tumors known to express EGFR, who received 720 milligram (mg) AFM24 on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).	Phase 2- CRC 480 mg Cohort A n=19 participants at risk Subjects with microsatellite stable (MSS) colorectal cancer (CRC) with rat sarcoma gene (RAS) wild-type tumor expressing EGFR who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).	Phase 2- ccRCC 480 mg Cohort B n=8 participants at risk Subjects with clear cell renal cell carcinoma (ccRCC) expressing EGFR who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).	Phase 2- NSCLC 480 mg Cohort C n=23 participants at risk Subjects with advanced or metastatic (non-small cell lung cancer) NSCLC with an epidermal growth factor receptor (EGFR) mutation who received 480 milligram (mg) AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle. A dose could be given over two days (split day dosing).
Nervous system disorders Bell's palsy	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Injury, poisoning and procedural complications Infusion related reaction	50.0% 1/2 • Number of events 4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	83.3% 5/6 • Number of events 42 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	75.0% 3/4 • Number of events 4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	80.0% 4/5 • Number of events 5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	50.0% 3/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	100.0% 6/6 • Number of events 9 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	66.7% 4/6 • Number of events 4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	78.9% 15/19 • Number of events 18 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	62.5% 5/8 • Number of events 7 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	82.6% 19/23 • Number of events 26 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Injury, poisoning and procedural complications Arthropod bite	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Injury, poisoning and procedural complications Clavicle fracture	50.0% 1/2 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Injury, poisoning and procedural complications Fall	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Injury, poisoning and procedural complications Humerus fracture	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Injury, poisoning and procedural complications Radiation pneumonitis	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Injury, poisoning and procedural complications Sunburn	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations Alanine aminotransferase increased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	50.0% 3/6 • Number of events 7 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	40.0% 2/5 • Number of events 4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	50.0% 3/6 • Number of events 5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	10.5% 2/19 • Number of events 4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations Aspartate aminotransferase increased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	50.0% 3/6 • Number of events 7 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	40.0% 2/5 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	33.3% 2/6 • Number of events 5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	15.8% 3/19 • Number of events 4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations Blood pressure decreased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 15 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations Blood bilirubin increased	50.0% 1/2 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	15.8% 3/19 • Number of events 4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations Blood alkaline phosphatase increased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	33.3% 2/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	50.0% 3/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations Neutrophil count decreased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	21.7% 5/23 • Number of events 7 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations Blood creatinine increased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations Weight decreased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	33.3% 2/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations Platelet count decreased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations White blood cell count decreased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations Activated partial thromboplastin time prolonged	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations Alpha tumour necrosis factor increased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations Blood lactate dehydrogenase increased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations C-reactive protein increased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations International normalised ratio increased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations Lipase increased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations Lymphocyte count decreased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations Serum ferritin increased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Investigations Urine output decreased	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Nausea	100.0% 2/2 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	50.0% 3/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	33.3% 2/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	66.7% 4/6 • Number of events 7 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 2/8 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	17.4% 4/23 • Number of events 4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Constipation	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	33.3% 2/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	50.0% 3/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	21.1% 4/19 • Number of events 5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	37.5% 3/8 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	8.7% 2/23 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Vomiting	50.0% 1/2 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	33.3% 2/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	33.3% 2/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	50.0% 3/6 • Number of events 6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	10.5% 2/19 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	8.7% 2/23 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Diarrhoea	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	33.3% 2/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	10.5% 2/19 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Abdominal distension	50.0% 1/2 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Abdominal pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	33.3% 2/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	15.8% 3/19 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	15.8% 3/19 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Ascites	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Dry mouth	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Proctalgia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	10.5% 2/19 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Abdominal pain lower	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Defaecation urgency	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Dyspepsia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Fistula of small intestine	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Inguinal hernia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Stomatitis	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Gastrointestinal disorders Toothache	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
General disorders Fatigue	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	66.7% 4/6 • Number of events 5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	50.0% 3/6 • Number of events 6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	10.5% 2/19 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	37.5% 3/8 • Number of events 4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	13.0% 3/23 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
General disorders Pyrexia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	50.0% 2/4 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	21.1% 4/19 • Number of events 4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	8.7% 2/23 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
General disorders Asthenia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	21.1% 4/19 • Number of events 4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 2/8 • Number of events 5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	13.0% 3/23 • Number of events 4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
General disorders Pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
General disorders Non-cardiac chest pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	8.7% 2/23 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
General disorders Oedema peripheral	50.0% 1/2 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	15.8% 3/19 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
General disorders Chills	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
General disorders Chest discomfort	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
General disorders Feeling of body temperature change	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
General disorders Influenza like illness	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
General disorders Infusion site extravasation	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
General disorders Temperature regulation disorder	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Blood and lymphatic system disorders Lymphopenia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 7 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	33.3% 2/6 • Number of events 12 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	15.8% 3/19 • Number of events 5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Blood and lymphatic system disorders Anaemia	50.0% 1/2 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	33.3% 2/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	21.1% 4/19 • Number of events 9 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	8.7% 2/23 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Blood and lymphatic system disorders Neutropenia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Skin and subcutaneous tissue disorders Dermatitis acneiform	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	66.7% 4/6 • Number of events 5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	50.0% 3/6 • Number of events 5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	13.0% 3/23 • Number of events 4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	33.3% 2/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	21.1% 4/19 • Number of events 6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 2/8 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	13.0% 3/23 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Skin and subcutaneous tissue disorders Rash	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	10.5% 2/19 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Skin and subcutaneous tissue disorders Rash macular	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	50.0% 3/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	10.5% 2/19 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	37.5% 3/8 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	8.7% 2/23 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	8.7% 2/23 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	8.7% 2/23 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Musculoskeletal and connective tissue disorders Axillary mass	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Musculoskeletal and connective tissue disorders Coccydynia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Musculoskeletal and connective tissue disorders Groin pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Dyspnoea	50.0% 1/2 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	50.0% 3/6 • Number of events 5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	10.5% 2/19 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	13.0% 3/23 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	21.7% 5/23 • Number of events 6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	8.7% 2/23 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Tachypnoea	50.0% 1/2 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Respiratory, thoracic and mediastinal disorders Wheezing	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Metabolism and nutrition disorders Decreased appetite	50.0% 1/2 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	17.4% 4/23 • Number of events 4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	33.3% 2/6 • Number of events 4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Metabolism and nutrition disorders Dehydration	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Nervous system disorders Headache	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	60.0% 3/5 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 2/8 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	13.0% 3/23 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Nervous system disorders Dizziness	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	50.0% 3/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	10.5% 2/19 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	8.7% 2/23 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Nervous system disorders Aphasia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Nervous system disorders Dysgeusia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Nervous system disorders Presyncope	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Nervous system disorders Somnolence	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Nervous system disorders Tremor	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations COVID-19	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	10.5% 2/19 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Lower respiratory tract infection	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Urinary tract infection	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Oral candidiasis	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Herpes zoster	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Klebsiella urinary tract infection	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Pneumonia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Rash pustular	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Rhinitis	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Skin infection	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Staphylococcal bacteraemia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Tooth infection	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Vascular device infection	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Vascular disorders Hypertension	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Vascular disorders Hypotension	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Vascular disorders Flushing	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Vascular disorders Deep vein thrombosis	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Vascular disorders Hot flush	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Psychiatric disorders Insomnia	50.0% 1/2 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	8.7% 2/23 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Psychiatric disorders Depression	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Psychiatric disorders Anxiety	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Psychiatric disorders Confusional state	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Psychiatric disorders Delirium	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	4.3% 1/23 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Eye disorders Chloropsia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Eye disorders Vision blurred	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	33.3% 2/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Eye disorders Conjunctival haemorrhage	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Eye disorders Diplopia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Eye disorders Eye pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Eye disorders Halo vision	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Renal and urinary disorders Proteinuria	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Renal and urinary disorders Dysuria	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Renal and urinary disorders Haematuria	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	25.0% 1/4 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	12.5% 1/8 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acrochordon	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cancer pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Cardiac disorders Tachycardia	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	40.0% 2/5 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Cardiac disorders Palpitations	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Immune system disorders Cytokine release syndrome	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	33.3% 2/6 • Number of events 3 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Hepatobiliary disorders Hepatic pain	50.0% 1/2 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Hepatobiliary disorders Jaundice	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	20.0% 1/5 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Congenital, familial and genetic disorders Hydrocele	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Reproductive system and breast disorders Testicular pain	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	16.7% 1/6 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Nasopharyngitis	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/19 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	8.7% 2/23 • Number of events 2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.
Infections and infestations Upper respiratory tract infection	0.00% 0/2 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/4 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/5 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/6 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	5.3% 1/19 • Number of events 1 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/8 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.	0.00% 0/23 • From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks The safety set consisted of all subjects who received at least one dose of AFM24.

Additional Information

Clinical Operations

Affimed GmbH

Phone: +49 62216530770

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The sponsor has the right to review communications for 90 days prior to public release (whereby the sponsor may ask to consider modifications to ensure necessary protection of sponsor's IP). Any publication shall be not made before the first multi-centre publication if the study is a part of a multi-centred clinical trial. Also, if a publication concerns the analyses of data from a multi-centred clinical trial, the communication shall make reference to the relevant multi-centre publication
Publication restrictions are in place

Restriction type: OTHER